The molecular distinction between seminomas and teratomas enables tailored therapeutic approaches: in seminomas, synthetic hsa-miR-138-5p mimics could reinforce apoptotic and anti-inflammatory pathways, while PD-1/PD-L1 checkpoint inhibitors may overcome STAT1- and CD8A-driven immune escape. This evidence concerns the gene CD8A and teratoma.